Oxidative stress in children receiving valproic acid - 10/08/11
Reprint requests: Dr. Kevin Farrell, Division of Neurology, Department of Pediatrics, University of British Columbia, Room K3-178, 4480 Oak Street, Vancouver BC, V6H 3V4 Canada.Résumé |
Objective |
To determine whether valproic acid (VPA) influences urinary levels of 15-F2t-isoprostane (15-F2t-IsoP), a marker of oxidative stress, in children.
Study design |
Morning urine samples were collected from children with epilepsy receiving VPA (n = 25), carbamazepine (n = 16), or clobazam (n = 12) for ≥ 4 weeks and from age-matched control subjects (n = 39). Urinary 15-F2t-IsoP levels were determined by enzyme-linked immunosorbent assay.
Results |
The mean (±standard deviation) urine 15-F2t-IsoP levels (nmol/mmol Cr) were: valproic acid (0.36 ± 0.15); carbamazepine (0.24 ± 0.10); clobazam (0.23 ± 0.10); control group (0.20 ± 0.09). Patients treated with VPA had significantly elevated 15-F2t-IsoP levels when compared with the control, carbamazepine, and clobazam groups (P < .05). Multiple linear regression analysis demonstrated that younger patient age and exposure to second-hand smoke were significant predictors of elevated urine 15-F2t-IsoP levels within the control group (r2 = 0.261, P = .05 and P = .01, respectively). Subjects not exposed to second-hand smoke receiving valproic acid therapy had a significantly elevated mean urine 15-F2t-IsoP level compared to subjects not exposed to second-hand smoke in the carbamazepine, clobazam and control groups (P < .05).
Conclusions |
These data demonstrate that treatment of children with VPA is associated with higher urinary levels of 15-F2t-IsoP, a marker of oxidative stress.
Le texte complet de cet article est disponible en PDF.Abbreviations : VPA, 15-F2t-IsoP, CBZ, CLB, ROS, QC
Plan
| Supported by the Canadian Institutes of Health Research (CIHR Grant MOP-13744). V.T. received a Canadian Institutes of Health Research Doctoral Research Award. X.W.T. received a Postdoctoral Fellowship from the Rx&D Health Research Foundation and Canadian Institutes of Health Research and an Incentive Award from the Michael Smith Foundation for Health Research. |
Vol 149 - N° 5
P. 692-696 - novembre 2006 Retour au numéro
Article précédent
- Bilateral anorchia in infancy: Occurence of micropenis and the effect of testosterone treatment
- D. Zenaty, F. Dijoud, Y. Morel, S. Cabrol, P. Mouriquand, M. Nicolino, C. Bouvatier, G. Pinto, C. Lecointre, C. Pienkowski, S. Soskin, M. Bost, A.M. Bertrand, A. El-Ghoneimi, C. Nihoul-Fekete, J. Léger
- Hearing loss in Turner syndrome
- Noriko Morimoto, Toshiaki Tanaka, Hidenobu Taiji, Reiko Horikawa, Yasuhiro Naiki, Yuji Morimoto, Nobuko Kawashiro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?